Blood levels of reduced halopertool versus clinical efficacy and extrapyramidal side effects of haloperidol
- 1 February 1997
- journal article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 21 (2) , 299-311
- https://doi.org/10.1016/s0278-5846(97)00007-9
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patientsPsychiatry Research, 1995
- A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia: With particular reference to drug resistanceSchizophrenia Research, 1993
- Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?Psychopharmacology, 1992
- Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patientsPsychiatry Research, 1991
- Haloperidol kinetics and clinical responseSchizophrenia Research, 1991
- Metabolites of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptorsEuropean Journal of Pharmacology, 1990
- Haloperidol reduction can be assayed in human red blood cellsCanadian Journal of Physiology and Pharmacology, 1989
- Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patientsBiological Psychiatry, 1989
- Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of PsychosesArchives of General Psychiatry, 1988
- Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazineAmerican Journal of Psychiatry, 1977